Showing results (151-160 of 168) with videos related to

Sort By:
Pageof 17
Journal of Neuro-Oncology|September 23, 2011
Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatmentHee-Jun Kim, Seock-Ah Im, Bhumsuk Keam, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 2, 2015
A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09Ki Hyeong Lee, Ji-Yeon Kim, Moon Hee Lee, et al.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2023
Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trialDae-Won Lee, Kyung Hae Jung, Kyung-Hun Lee, et al.
Journal of Hypertension|June 6, 2017
Relation between secondhand smoke exposure and cardiovascular risk factors in never smokersSehun Kim, Si-Hyuck Kang, Donghoon Han, et al.
Korean Circulation Journal|March 23, 2026
Temporal Trend of Cardiovascular Disease Burden Among Cancer Patients Between 2005 and 2022: Nationwide Population-Based Cohort Study in South KoreaIksung Cho, Seonhwa Lee, Jaehyeong Cho, et al.
Cytokine|March 26, 2021
Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10-13)Ju Won Kim, Soohyeon Lee, Hye Sook Kim, et al.
The Lancet. Oncology|November 1, 2019
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trialYeon Hee Park, Tae-Yong Kim, Gun Min Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2025
Proliferation of tumor-related regulatory T cells in circulation dictates efficacy of chemoimmunotherapy in triple-negative breast cancerSeung Hyuck Jeon, Koung Jin Suh, Sungmin Jung, et al.
The Lancet. Oncology|February 20, 2025
Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 studyHee Kyung Ahn, Ji-Yeon Kim, Kyung-Hun Lee, et al.
Breast (Edinburgh, Scotland)|August 27, 2022
Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B)Sung Hoon Sim, Jeong Eun Kim, Min Hwan Kim, et al.
Pageof 17